Grove Instruments Inc., a medical device company focused on glucose monitoring technology, has raised $2.45 million in Series B equity financing from 11 investors, according to SEC filings.

Grove Instruments has developed cutting edge, patented technology that will provide a long sought alternative to the pain and inconvenience diabetic individuals experience every day with current glucose monitoring.

The same technology will also allow organizations and physicians to quickly and painlessly screen people for diabetes and pre-diabetes.